Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
90 participants
INTERVENTIONAL
2023-03-01
2023-04-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Association of Anticholinergic Burden With Onset of Delirium in Older Adults With Alzheimer Dementia:
NCT05055895
Effect of Early Memantine Administration on Outcome of Patients With Moderate to Severe Traumatic Brain Injury
NCT05531383
The Efficacy and Safety of Tropisetron in Preventing Emergence Delirium
NCT04027751
A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression
NCT03044249
Impact of Pharmacotherapy Management in Patients With Alzheimer's Disease
NCT02222181
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Quetiapine
The patients with multiple risks for delirium will receive 25 mg/day PO
Quetiapine
The patients will be randomly divided into two equal groups group Q and group C. Randomization will be done by computer-generated number lists and using opaque sealed envelopes.
Non pharmacological preventive bundle
The patients will only be monitored with application of delirium preventive bundle without pharmacological agent
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quetiapine
The patients will be randomly divided into two equal groups group Q and group C. Randomization will be done by computer-generated number lists and using opaque sealed envelopes.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Sedated patients
* Hypotensive patients
* Immobilized patients
* Patients with visual or auditory impairment
Exclusion Criteria
* Patients diagnosed with delirium
* Contraindication for delirium
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Walid Kamel
Role: PRINCIPAL_INVESTIGATOR
Faculty of medicine, Ain Shams University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams University
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Quetiapine
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.